Intensive Cancer Screening After Cryptogenic Stroke
Recruiting now NCT05733416
Run by Ottawa Hospital Research Institute · for 18 and older · All sexes
What this study is about
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT (F-fluorodeoxyglucose positron emission/computed tomography) in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke.
Who can join (things the study team will check)
✅ You may be able to join if…
- adults ≥18 years
- presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)
- patient or delegate willing and able to provide informed consent.
🚫 You may not be able to join if…
- contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes)
- active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)
Where this trial is running
- The Ottawa Hospital, Ottawa, Ontario, Canada
Who to contact
Dariush Dowlatshahi, MD PhD · 613-798-5555 · ddowlat@toh.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05733416.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.